NAV3
Overview
NAV3 (Neuron Navigator 3) encodes a member of the neuron navigator protein family, which guides axonal growth cone migration. In dedifferentiated liposarcoma (DDLPS), NAV3 resides within the hallmark 12q13~15 amplicon and is recurrently amplified alongside MDM2, CDK4, HMGA2, and FRS2.
Alterations observed in the corpus
- NAV3 amplification was present in 60% of DDLPS cases (n=50) in the TCGA sarcoma cohort; NAV3 is located at 12q13~15, the defining amplicon of DDLPS; copy number and mRNA levels were significantly correlated (p≤0.001) PMID:29100075
Cancer types (linked)
- DDLPS (Dedifferentiated Liposarcoma): NAV3 amplification observed in 60% of DDLPS cases as part of the 12q13~15 amplicon; co-amplified with MDM2 (100%), CDK4 (92%), HMGA2 (76%), and FRS2 (96%) PMID:29100075
Co-occurrence and mutual exclusivity
Therapeutic relevance
- NAV3 amplification has not been directly therapeutically targeted; its co-amplification with MDM2 and CDK4 in DDLPS is relevant to the therapeutic context of MDM2 inhibitors and CDK4/6 inhibitors being evaluated in DDLPS.
Open questions
- Whether NAV3 amplification has functional consequences independent of MDM2/CDK4 co-amplification, or is a bystander within the 12q13~15 amplicon, has not been established.
Sources
This page was processed by crosslinker on 2026-05-15.